deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT06010004

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)

A Phase 3, Long-term Safety Study of LY3502970 in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone or in Combination With Oral Antihyperglycemic Medications (ACHIEVE-J)

Sponsor: Eli Lilly and Company

Interventions Orforglipron
Updated 15 times since 2023 Last updated: Jul 11, 2025 Started: Sep 28, 2023 Primary completion: Jun 5, 2025 Completion: Jun 5, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06010004, this PHASE3 trial focuses on Type 2 Diabetes and remains completed. Sponsored by Eli Lilly and Company, it has been updated 15 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Aug 2025 · 3 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

15 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  3. May 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

Show 10 earlier versions
  1. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  5. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE3

  6. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE3

  7. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE3

  8. Nov 2023 — Feb 2024 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  9. Oct 2023 — Nov 2023 [monthly]

    Not Yet Recruiting PHASE3

  10. Sep 2023 — Oct 2023 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .